Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin by Balligand, Thomas et al.
Available at:
http://hdl.handle.net/2078.1/173192
[Downloaded 2019/04/18 at 23:46:35 ]
"Pathologic activation of thrombopoietin receptor and JAK2-
STAT5 pathway by frameshift mutants of mouse calreticulin"
Balligand, Thomas ; Achouri, Younes ; Pecquet, Christian ;
Chachoua, Ilyas ; Nivarthi, Harini ; Marty, Caroline ; Vainchenker,
William ; Plo, Isabelle ; Kralovics, Robert ; Constantinescu, Stefan N.
Document type : Article de périodique (Journal article)
Référence bibliographique
Balligand, Thomas ; Achouri, Younes ; Pecquet, Christian ; Chachoua, Ilyas ; Nivarthi, Harini ;
et. al. Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift
mutants of mouse calreticulin. In: Leukemia, Vol. 30, no. 8, p. 1775-1778 (2016)
DOI : 10.1038/leu.2016.47
LETTER TO THE EDITOR
Pathologic activation of thrombopoietin receptor and
JAK2-STAT5 pathway by frameshift mutants of mouse
calreticulin
Leukemia advance online publication, 18 March 2016;
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Frameshifting (−1/+2) mutations in the exon 9 of the calreticulin
gene (CALR) lead to the development of BCR-ABL-negative
myeloproliferative neoplasms (MPNs) in humans under the forms
of essential thrombocythemia (ET) and myeloﬁbrosis.1,2 We have
shown that mutant human CALR proteins require interaction with
the thrombopoietin receptor (TpoR) to exert an oncogenic
activation of the JAK/STAT pathway.3,4 Here, we report that
homologous mutations in the murine Calr gene result in a highly
similar, but not identical mutant CALR protein as found in human
patients that also requires TpoR interaction to be able to activate
the JAK/STAT pathway.
CALR is a highly conserved protein throughout the species:5
both human and mouse CALR transcript sequences share 88% of
base-pair identity (1098/1254 bp, human sequence as reference).
Similarly, mouse and human wild-type CALR protein amino acid
sequences are highly similar, but not identical: 94.25% identity;
377/400 exact same AA with human sequence as reference
(Supplementary Figure 1A). Modeling the charge and structure of
the mutant CALR proteins, we observed high levels of similarity in
charge and predicted properties (Supplementary Figures 1C and
D). By comparing type-1 and type-2 human mutant CALR amino
acid sequences with the mouse wild-type (WT) CALR sequence, we
created three murine CALR mutants homologous to their human
counterparts for our study: del52 (type 1), ins5 (type 2) and del61
(type 1) (Supplementary Figures 1B–D), with del61 being highly
similar to del52, but more easily engineered in the murine
genome using the CRISPR/Cas9 system (Supplementary Figure 2).
Interestingly, a very similar 61 bp deletion in the human CALR
gene (c.1099_1159del) has already been reported in the MARIMO
myeloid cell line6 issued from a patient treated for acute
myeloblastic leukemia with maturation with Busulfan who had a
history of ET.7
The mCalr del52, ins5 and del61 complementary DNAs were
obtained using the QuickChange mutagenesis kit from Agilent,
Santa Clara, CA, USA.8 STAT5 activation by the murine CALR
mutants was subsequently conﬁrmed by dual-luciferase reporter
assay by transiently transfecting mCalr constructs in γ2A cells
(a JAK2-deﬁcient human ﬁbrosarcoma derived cell line)9 and using
the Dual-Glo Kit from Promega, Madison, WI, USA as previously
described.3 For CRISPR/Cas9 engineering of mCalr del61 Ba/F3
cells, oligos encoding designed single guide RNAs were cloned
into the CRISPR/Cas9 px330 vector (gift from Feng Zhang:10
Addgene #42230). Efﬁciency of the obtained px330-sg1 and
px330-sg2 constructs to target and cleave Calr exon 9 was veriﬁed
by cloning the Calr exon 9 sequence in the pCAG-EGxxFP vector
(gift from Ikawa Mashiko:11 Addgene # 50716) and transiently
transfecting both constructs in HEK-293T cells to quantify
enhanced green ﬂuorescent protein expression after 48 h of
culture. After conﬁrmation, either parental or TpoR-expressing
Ba/F3 cells were electroporated with either both px330-sg1, –sg2
constructs or empty pMX-IRES-GFP. Cells were immediately kept in
Interleukin-3 containing medium for 48 h before subsequent
assays. We conﬁrmed the presence of the 61 bp deletion in the
Calr gene in TpoR/CRISPR cells by genomic DNA extraction and
polymerase chain reaction ampliﬁcation of the Calr exon 9 locus.
All Ba/F3 populations were then used in proliferation assays by
automatic cell counting or CellTiter-Glo assay (Promega, by
following manufacturer’s protocol) at different timepoints, and
were lysed for western blotting. Lastly, ﬂuorescence activated cell
sorting (FACS) analysis of these Ba/F3 populations was performed
using PE-linked anti-CD110 (TpoR) antibody from Miltenyi Biotec
(Leiden, Netherlands) using a FacsVerse cytometer from BD
technologies (Durham, NC, USA). Detailed procedures are
described in Supplementary Material.
As it is the case for their human CALR mutant counterparts,3,4
mCALR del52, mCALR ins5 and mCALR del61 were able to activate
the JAK-STAT pathway when compared with mCALR WT in
presence of human TpoR (Figure 1a and Supplementary
Figure 10). This was also the case for mCALR mutants with
murine TpoR (Supplementary Figure 3). In the case of granulocyte
colony-stimulating factor receptor (GCSFR), mCALR mutants were
able to activate the JAK-STAT pathway to a lower extent than with
TpoR. No differences between mCALR WT and mCALR mutants
were noticeable when cotransfected with EpoR.
Next, we show that Ba/F3 endogenously expressing mCALR
del61 after CRISPR/Cas9 modiﬁcation are able to proliferate in the
absence of IL-3, but only if also expressing TpoR. All other cell
populations, including parental Ba/F3 cells subjected to CRISPR/
Cas9, stopped proliferating and underwent apoptosis in the
absence of IL-3 (Figure 1b, Supplementary Figure 4). Ba/F3-
expressing GSCFR instead of TpoR were not able to proliferate in
long-term conditions (472 h) after CRISPR modiﬁcation (data not
shown). Sequential dilutions allowed isolation of a TpoR-
expressing Ba/F3 clone homozygous for a 4 bp deletion of the
Calr gene, resulting in a close to type-2 mCALR mutant allowing
the cells to proliferate in the absence of cytokines (Supplementary
Figure 5). We subjected cytokine-independent proliferating TpoR/
CRISPR Ba/F3 cells to 1 μM Ruxolitinib and observed that treated
cells died after 48 h whereas control group proliferated normally
(Figure 1b) demonstrating that JAK-STAT is therefore the key
pathway for pathological proliferation of mCALR mutant cells and
conﬁrms that type-1 JAK2 inhibitors would be a viable treatment
regimen in CALR-driven MPNs.12,13 We next asked whether excess
mCALR WT would act as a hypothetical competitive inhibitor of
the mutant mCALR del61 by interaction with TpoR. Cytokine-
independent proliferating TpoR/CRISPR Ba/F3 cells were trans-
duced to overexpress mCALR WT (Supplementary Figure 6), they
rapidly acquired autonomous growth and we could not detect any
proliferation difference compared with control cells by automatic
cell counting (Figure 1b).
All populations were next subjected to western blot for
detecting constitutive and ligand-induced signaling in the
presence of endogenously-expressed mCALR mutants
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(Figure 2a). A separate population of Ba/F3 TpoR/CRISPR that was
preselected for a week in IL-3 free medium was also included to
ensure selection for mCALR mutant cells. These last cells exhibited
the presence of phosphorylated JAK2, phosphorylated TYK2 and
phosphorylated STAT5/3/1 in the absence of ligand in contrast to
all the other populations. Importantly, phosphorylated JAK2, TYK2,
STAT5/3/1 were undetectable in the absence of ligand in Ba/F3
TpoR/CRISPR that were not preselected because mCALR mutant
cells did not have time to achieve clonal superiority during the
short selection (4 h) before lysis. Interestingly, in presence of Tpo,
preselected TpoR/CRISPR cells show a weaker JAK2, TYK2, STAT5-
/3/1 phosphorylation response than other TpoR-expressing
populations. This could be due to a decrease of the surface levels
of the TpoR in presence of mCALR mutants. We also searched for
differences in Ras/MAPK/Erk and PI3’K pathway activation but
could not detect any constitutive AKT phosphorylation and very
weak MAP-kinase phosphorylation for the preselected CRISPR/
TpoR cells. We also show that cells subjected to CRISPR show
a second band o48 kDa after anti-CALR staining, conﬁrming the
presence of type-1 mutant mCALR.
Based on our Western blot results showing that cytokine-
independent TpoR/CRISPR Ba/F3 cells show lower levels of
Tpo-dependent activation of the JAK-STAT pathway, we assessed
cell surface levels of TpoR by FACS analysis. We show that, in the
presence of the mutant mCALR, the surface levels of TpoR are
down-regulated (Figure 2b). This may result from persistent
signaling with internalization from the surface and from trafﬁc
defects induced by mutant mCALR within the secretory pathway
or other cellular compartments. We have already shown that del52
and ins5 human CALR mutants induce a block in TpoR maturation
and presence of endoglycosidase H-sensitive TpoR at the cell
surface.3 Although the surface levels of TpoR are decreased in our
preselected TpoR/CRISPR Ba/F3 cells, the total TpoR levels remain
the same on Western Blot (Figure 2a). Similarly, as TpoR was
transduced using a pMX-IRES-GFP construct in these cells, GFP
levels are correlated with the total level of expression of TpoR. By
FACS, we show that the preselected TpoR/CRISPR Ba/F3 cells have
the same or slightly higher expression of GFP than the other
unselected TpoR/CRISPR or TpoR/empty vector cells, meaning that
the TpoR expression is certainly not reduced in these cells
(Figure 2c).
With this report, we show that the homologous mCALR del52,
ins5 and del61 mutants also activate TpoR signaling via JAK-STAT
pathway and behave similarly to the human counterparts, and
Figure 1. mCALR mutants activate the JAK-STAT pathway and enable cytokine-independence of Ba/F3 – TpoR cells. (a) mCALR mutants
activate STAT5 when co-expressed with TpoR and GCSFR, but not EpoR in vitro when compared with mCALR WT. γ2A cells were transiently
transfected with SpiLuc, a ﬁreﬂy luciferase reporter under a STAT5-speciﬁc promoter and a renilla luciferase reporter under a TK promoter as
transfection control and complementary DNAs coding for either mCALR-WT, del52, ins5, del61 or empty vector (pMX-IRES-GFP), along with
cytokine receptor (TpoR, GCSFR or EpoR), JAK2 and STAT5. Ligands or control medium were added 4 h after transfection. Cells were cultivated
for 24 h before lysis and readings by luminometer. Shown are averages of separate experiments+s.d. (N= 7 for TpoR, N= 4 for GCSFR, N= 2 for
EpoR); each experiment being performed with three biological repeats for each condition (triplicates). *Po0.05, **Po0.01, ***Po0.001.
Nonparametric multiple comparisons using Steel’s test with a control group (CALR WT no ligand). (b) (Left) Only TpoR/CRISPR Ba/F3 cells
are able to proliferate in absence of IL-3. Ba/F3 cells, either parental or transduced to express TpoR, were electroporated with either both
px330-sg1 and px330-sg2 constructs or an empty vector. Cells were grown 48 h in the presence of IL-3 and then subsequently washed and
put into IL-3 free growth medium on a 6-well plate. Initial total count at day 0 was 175 000 cells for all populations. Measurements were done
using an automatic Coulter cell counter. Results are from one experiment (average of three biological repeats+s.d.) as representative of three
separate experiments showing the same results. (Middle) Ruxolitinib inhibits proliferation of selected TpoR/CRISPR Ba/F3 cells signifying the
critical importance of the JAK2/STAT5/3/1 pathway in the case of CALR mutant activation of TpoR. TpoR/CRISPR Ba/F3 cells that were able to
grow independently of cytokines were washed three times in PBS and put at a starting concentration of 100 000 cells/ml on a 6-well plate
in RPMI-Hepes+10% FBS free of any cytokines. 1 μl Ruxolitinib, diluted in DMSO was added at a ﬁnal concentration of 1 μM to three wells. 1 μL
DMSO was added to the other three wells. Measurements were done using an automatic Coulter cell counter. Results are from one
experiment (average of three biological repeats+s.d.) as representative of three separate experiments showing the same results. (Right)
mCALR WT overexpression does not interfere with mCALR mutant oncogenic activity. Selected TpoR/CRISPR cells that were able to grow
independently from IL-3 stimulation were transduced with either a mCalr-WT/mCherry or empty/mCherry retrovirus construct and sorted by
FACS using the mCherry marker. After sorting, cells were washed and put into IL-3 free growth medium on a 6-well plate, three wells per
condition. Initial total cell count at day 0 was 200 000 cells for all conditions. Measurements were done using an automatic Coulter cell
counter. Results are from one experiment (average of three biological repeats+s.d.) as representative of three separate experiments showing
the same results. DMSO, dimethyl sulfoxide; FBS, fetal bovine serum; PBS, phosphate-buffered saline.
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Figure 2. Signaling patterns and surface TpoR changes induced by mCALR mutants. (a) Parental or TpoR-expressing Ba/F3 cell populations
previously electroporated with either CRISPR/Cas9 constructs targeting Calr exon 9 to create the del61 mutation (+CRISPR) or an empty vector
(+empty) were washed three times to remove any IL-3 and put to grow in IL-3 free medium for at least 4 h to abolish all IL-3 signaling, in the
presence or absence of recombinant Tpo at 20 ng/ml. A subset of TpoR+CRISPR Ba/F3 were washed free of IL-3, 1 week before the
experiment, and selected in IL-3 and Tpo free medium, to ensure clonal dominance of mutant mCALR-expressing cells (+CRISPR 1 week
selection). Only cells that were preselected a week before showed more phosphorylated JAK2, STAT5, STAT3, STAT1, MAPK and TYK2 in the
absence of ligand when compared with the other populations, demonstrating an activation of these pathways by the mutant mCALR. TpoR
+CRISPR Ba/F3 that were not preselected have undetectable levels of phosphorylated JAK2, STAT5, STAT3, STAT1, MAPK and TYK2 as the
mCALR mutant cells have not had time to achieve clonal dominance. No differences were observable for phosphorylated AKT (threonine 308)
or JAK1. Preselection 1 week before western blotting was not possible on other than TpoR+CRISPR Ba/F3 populations because those cells die,
as shown in Figure 1b and Supplementary Figure 4. Total levels of JAK2, STAT5, STAT3, STAT1, MAPK, AKT, JAK1, TYK2 and β-actin are shown
as references. hemagglutinin-tagged TpoR was only detected in TpoR-expressing cells as intended. A second CALR band is visible in CRISPR
cells, corresponding to the mCALR mutants (red arrow tip). Preselected TpoR+CRISPR (1 week selection) Ba/F3 have a stronger presence of
mCALR mutant than TpoR+CRISPR (not preselected) Ba/F3 as the preselection allowed the mCALR mutant cells to achieve clonal superiority.
These results are from one experiment as representative of three separate experiments showing similar results. (b) FACS analysis of
electoporated Ba/F3 populations. Surface TpoR level of all Ba/F3 populations was assessed by FACS using a PE-linked anti-CD110 (TpoR)
antibody. Only the TpoR+CRISPR (1 week selection) Ba/F3 preselected in absence of IL-3 show a decrease of surface TpoR levels (black arrow
tip). This is representative of three separate experiments. Again, TpoR+CRISPR Ba/F3 that were not preselected do not show a decrease in
surface TpoR as the mCALR mutant cells have not achieved clonal superiority. (c) Total GFP levels of cells analyzed in (b) are also shown: as
TpoR was expressed using a pMX-IRES-GFP vector, expression of GFP is correlated to TpoR expression. Only populations expressing TpoR
show a signiﬁcant level of GFP, with the TpoR+CRISPR (1 week selection) Ba/F3 preselected in IL-3 free medium showing a slightly increased
GFP expression (blue arrow tip). These results are from one experiment as representative of three separate experiments showing same results.
Below are the calculated geometric medians for each population, determined from 10 000 events per gate.
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that creation of a del61 endogenous Calr mutation rapidly leads
to cytokine-independent transformation of Ba/F3 TpoR, but not
Ba/F3 parental or Ba/F3 GCSFR. The previously reported ability of
human CALR del52 to transform parental Ba/F3 cells1 was
explained by induction of expression of the endogenous mouse
MPL/TpoR of Ba/F3 cells.14 In that study, a global CRISPR/Cas9
approach was also used to target Calr exon 9. Frameshift
mutations in all three frames were obtained in Ba/F3 cells, but
only − 1/+2 frameshift mutations transformed Ba/F3 TpoR cells;
those were different than our Calr del52, ins5 and del61
mutations.14 Our experiments allowed us to study signaling in
more physiologic expression conditions, and to observe that, due
to cell surface TpoR down-modulation, response to ligand was
blunted and also that mCALR WT does not interfere with the
oncogenic properties of mutant CALR, which is relevant to the
heterozygous state of CALR mutation in MPN patients.15 These
results also pave the way for the creation of new mouse models of
mutant CALR-driven MPNs using the CRISPR/Cas9 tool to easily
engineer a type-1 (or type-2) mutation in mouse zygotes, which
would be different from the human CALR dependent mouse
model generated by retroviral bone marrow transduction and
transplantation.4
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